GlassScriptPhysician profile
Justin W Terry
NPI 1235453093
$19,351.76
in general payments reported to CMS, 2019-2025
74 companies · $3,722 in 2025
The $3,722 reported for 2025 was more than what 97% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,621 · 2020: $2,083 · 2021: $2,288 · 2022: $2,568 · 2023: $2,871 · 2024: $3,199 · 2025: $3,722.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,792.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,791.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $1,846.20 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $1,635.54 | 2019-2025 | Dupixent |
| Amgen INC. | $1,560.10 | 2019-2025 | Otezla, Tezspire, Repatha |
| Glaxosmithkline, LLC. | $1,453.04 | 2019-2025 | Nucala, Shingrix, Arexvy |
| Abbvie INC. | $1,139.25 | 2019-2025 | Vraylar, Ubrelvy, Qulipta |
| Astrazeneca Pharmaceuticals LP | $1,132.14 | 2019-2025 | Fasenra, Lokelma, Farxiga |
| Novo Nordisk INC | $1,063.03 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $830.71 | 2019-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $561.42 | 2021-2025 | |
| Antares Pharma, INC. | $554.78 | 2019-2025 | Xyosted |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $554.21 | 2022-2025 | Caplyta |
| Takeda Pharmaceuticals U.S.A., INC. | $518.11 | 2019-2025 | Trintellix, Cuvitru |
| Otsuka America Pharmaceutical, INC. | $473.12 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Bayer Healthcare Pharmaceuticals INC. | $469.41 | 2022-2025 | |
| Lilly USA, LLC | $404.25 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
Show all 74 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Justin Terry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.